Forte Biosciences (FBRX) Financials

$76.99

$0.00 (0.00%)

As on 28-Aug-2026 09:30EDT

Market cap

$1,634 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

8.9

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	-0.01	0.06	0.04	0.01	--	0.04
Gross Profit	0.01	-0.06	-0.04	-0.01	--	-0.04
Operating Expenses	90.02	70.66	36.56	32.48	13.90	21.49
Operating Profit (EBIT)	-90.00	-70.66	-36.60	-32.49	-13.90	-21.49
Other Income	--	--	--	--	--	--
Profit before Tax	-86.33	-68.34	-35.48	-31.48	-13.88	-21.71
Provision for Tax	1.60	1.04	-35.48	--	-0.02	-0.20
Profit after Tax (Net Income)	-87.94	-69.38	-35.48	-31.48	-13.86	-21.71
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-13.88	-21.71

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	183.79	60.99	52.48	35.31	38.82	41.55
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	1.66	1.04	--	--	1.15	0.95
Current Liabilities	20.29	20.75	9.08	3.67	3.18	1.76
Total Liabilities	226.03	82.78	61.56	38.98	42.00	43.31

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	2.64	2.19	0.22	0.65	0.49	0.79
Current Assets	203.10	80.59	61.35	38.33	41.51	42.52
Total Assets	226.03	82.78	61.56	38.98	42.00	43.31
Total Debt*	--	--	--	--	--	--
Net Current Assets	182.81	59.84	52.27	34.66	38.33	40.76

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-50.88	-30.75	-28.71	-8.19	-16.68
Cash Flow from Investing Activities	--	36.23	-35.99	0.05	--	--
Cash from Financing Activities	--	69.36	51.86	24.68	7.24	-0.04
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-4.60	-3.88	-5.55	-0.87	-16.50	-36.78
Cash EPS ($)	--	-3.88	-5.54	-0.87	-16.50	-36.72
Adjusted Book Value ($)	--	3.41	8.21	0.97	46.21	70.40
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-2.85	-4.81	-0.79	-9.74	-28.26
Free Cash Flow per Share ($)	--	-2.85	-4.81	-0.79	-9.74	-28.26

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-122.28	-80.82	-84.92	-34.50	-43.19
ROE (%)	-71.85	-122.28	-80.82	-84.92	-34.50	-43.19
ROA (%)	-51.28	-96.13	-70.57	-77.74	-32.50	-41.53
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	-48.86	-92.62	-12.71	-126.51	35.99	53.30
Net Profit Growth (%)	-107.14	-95.54	-12.71	-127.07	36.14	53.30
EPS Growth (%)	42.41	0.30	-5.41	0.95	0.55	0.59
Book Value Growth (%)	-7.98	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-7.02	-4.09	-0.95	-0.06	-0.06
Price / Book Value	8.89	7.99	2.77	0.85	0.02	0.03
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	1.87	-6.01	-2.45	0.23	2.90	1.88
Close Price ($)	21.25	27.27	22.71	20.55	25.00	53.50
High Price ($)	35.80	31.27	28.68	32.25	57.00	1,089.25
Low Price ($)	9.12	4.91	4.11	9.50	22.44	49.00
Market Cap ($ Cr)	1,634.43	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	--	--	--	--	--
Short term debt to equity ratio	--	--	--	--	--	--
Current Ratio	10.01	3.88	6.76	10.45	13.06	24.19
Quick Ratio	10.01	--	--	--	--	--
Interest Coverage	--	--	--	--	-817.41	-97.78

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	42,426.07	29,515.01	52,291.63	--	11,089.40
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.